Correction: Case Study on Dual PD-1/CTLA-4 Checkpoint Inhibition in Cancer

Overview

This correction clarifies that the article regarding dual PD-1/CTLA-4 checkpoint inhibition in advanced pulmonary squamous cell carcinoma was misclassified as a review instead of a case report. The original findings remain unchanged.

Background

The use of immune checkpoint inhibitors targeting PD-1 and CTLA-4 has transformed treatment strategies for advanced lung cancer. However, challenges such as primary resistance and immune-related adverse events persist, necessitating ongoing research and accurate reporting of clinical findings.

Data Highlights

No numerical data or trial results are presented in the correction article.

Key Findings

• The article was incorrectly categorized as a review; it is a case report.
• QL1706 is a bifunctional PD-1/CTLA-4 product showing promise in advanced solid tumors.
• Current WHO guidelines recommend specific regimens for patients with multidrug-resistant tuberculosis.
• Dual checkpoint inhibition may offer different outcomes compared to single-agent therapies in certain patient subgroups.
• Ongoing studies are evaluating the efficacy and safety of dual checkpoint blockade in various cancer types.

Clinical Implications

Accurate classification of clinical reports is essential for the integrity of medical literature. Clinicians should remain informed about the evolving guidelines for treating advanced lung cancer and associated conditions like multidrug-resistant tuberculosis.

Conclusion

This correction emphasizes the importance of proper article classification while maintaining the integrity of the reported findings on dual checkpoint inhibition in cancer treatment.

Related Resources & Content

1. Huang L, Li H, Front. Oncol., 2026 -- Correction: Case Study on Dual PD-1/CTLA-4 Checkpoint Inhibition
2. The ASCO Post — Advanced NSCLC: Dual vs Single Checkpoint Blockade
3. the asco post — Survival With Dual CTLA-4 and PD-L1/PD-1 Blockade in Advanced NSCLC
4. Frontiers in Immunology — Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review
5. The ASCO Post — Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy
6. Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
7. Survival With Dual CTLA-4 and PD-L1/PD-1 Blockade in Advanced NSCLC
8. Case Report: PD-1/CTLA-4 dual checkpoint blockade(QL1706) in advanced pulmonary squamous cell carcinoma complicated by multidrug-resistant tuberculosis after multiple lines of immunotherapy
9. Summary of recommendations - WHO consolidated guidelines on tuberculosis - NCBI Bookshelf
10. Frontiers | Tuberculosis infection following administration of immune checkpoint inhibitors: a real world observational study
11. Clinical Testing and Diagnosis for Tuberculosis | Tuberculosis (TB) | CDC